Search
Bizalimogene ralaplasmid
go.drugbank.com/drugs/DB16113InvestigationalAnal or Anal/peri-anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2). … Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related
Fluoride ion
go.drugbank.com/drugs/DB11257ApprovedInvestigationalHaving a chemical formula of F−, fluoride ion is the simplest inorganic, monatomic anion of fluorine with basic properties. It is considered a trace element. Fluoride ions are found in various minerals but are only present in trace amoun...
Mixtures: Tri-Vi-Flor, Poly-Vi-Flor with IronAntrafenine
go.drugbank.com/drugs/DB01419ApprovedAntrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen. It is not widely used as it has largely been replaced by newer drugs.
Olmutinib
go.drugbank.com/drugs/DB13164InvestigationalOlmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016.
Articaine
go.drugbank.com/drugs/DB09009ApprovedInvestigationalArticaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.
Mixtures: FULLCAIN FORT AMPUL , 100 AMPUL, FULLCAIN FORT AMPUL , 20 AMPULTriprolidine
go.drugbank.com/drugs/DB00427ApprovedFirst generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.
Categories: Antihistamines for Systemic UseChlorphenesin
go.drugbank.com/drugs/DB00856ApprovedCategories: Antifungals for Topical Use, Antifungals for Dermatological UseTofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[L46133] In June of 2024, it was additionally approved by the EMA for the same indication. … [A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation.
Pyrrolizidine
go.drugbank.com/drugs/DB19159InvestigationalPyrrolizidine is under investigation in clinical trial NCT05898373 (Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC).